Richard Knapp
General Practice · Madison, WVNPI 1134407018
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.4%), food and beverage and education — rather than concentrated in one kind of arrangement. Indivior Inc. accounts for 65.8% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2020 at $6,083 and has fallen 85.8% since, to $865 in 2025. Among general practice clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $45.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$11K
- Novo Nordisk$1K
- Pfizer$791
- AstraZeneca$684
- AbbVie$398
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$292
- plus $2K from 34 others
What the payments were for
- Speaking & faculty fees$9,50059%
- Food & beverage$6,47240%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 45 | $10,511 |
| Novo Nordisk | 63 | $1,016 |
| Pfizer | 47 | $791 |
| AstraZeneca | 26 | $684 |
| AbbVie | 25 | $398 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $292 |
| Novartis | 14 | $252 |
| GSK | 15 | $237 |
| Abbott | 10 | $230 |
| Lilly USA, LLC | 14 | $225 |
| Boehringer Ingelheim | 9 | $157 |
| Zynex Medical, Inc. | 1 | $148 |
| Amgen | 7 | $99 |
| Merck | 4 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| E.r. Squibb & Sons, L.L.C. | 5 | $79 |
| Dexcom, Inc. | 4 | $69 |
| Bayer | 4 | $63 |
| Amarin Pharma, Inc. | 4 | $61 |
| Pear Therapeutics (US), Inc. | 3 | $57 |
| Astellas Pharma US Inc | 2 | $40 |
| Scilex Pharmaceuticals Inc. | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $34 |
| Johnson & Johnson | 2 | $32 |
| Braeburn Inc. | 2 | $30 |
| Averitas Pharma Inc. | 1 | $29 |
| Medtronic | 1 | $27 |
| Exact Sciences | 1 | $26 |
| QOL Medical, LLC | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Alkermes, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Valinor Pharma, LLC | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,984 in reported general payments places this provider in the 95th percentile of 437 general practice providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 133 | $145,429 |
| EliquisApixaban | 285 | $92,635 |
| XareltoRivaroxaban | 188 | $76,484 |
| JardianceEmpagliflozin | 127 | $56,614 |
| LinzessLinaclotide | 89 | $50,307 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $48,640 |
| JanuviaSitagliptin Phosphate | 138 | $46,295 |
| FarxigaDapagliflozin Propanediol | 70 | $40,198 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $30,244 |
| MounjaroTirzepatide | 22 | $22,855 |
| EntrestoSacubitril/Valsartan | 36 | $20,201 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 195 | $18,880 |
| VascepaIcosapent Ethyl | 86 | $17,777 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 867 | $16,513 |
| TrulicityDulaglutide | 20 | $14,741 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,016 | $157,767145 claims |
| PfizerEliquis | $791 | $92,635285 claims |
| Johnson & JohnsonXarelto | $32 | $76,484188 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $684 | $70,442108 claims |
| GSKTrelegy Ellipta, Arexvy | $237 | $57,74590 claims |
| Boehringer IngelheimJardiance | $157 | $56,614127 claims |
| AbbVieLinzess | $398 | $50,30789 claims |
| MerckJanuvia | $79 | $46,295138 claims |
| Lilly USA, LLCMounjaro, Trulicity | $225 | $37,59642 claims |
| NovartisEntresto | $252 | $20,20136 claims |
| BayerKerendia | $63 | $12,28225 claims |
| Astellas Pharma US IncMyrbetriq | $40 | $9,30827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 437 general practice providers in West Virginia.
Other general practice in Madison
- Harold HowellMadison$2K
- John VeltmanMartinsburg$15K
- Samuel O'DellHurricane$11K
- Elyse ReihnerBeckley$8K
- Aimee MerrittHuntington$6K
- Gerard VeltriClarksburg$6K
- Reginald OpimoHuntington$6K
- Douglas FlorenceParkersburg$6K
- Joshua ChapmanSouth Charleston$6K
- Chad PaterraWeirton$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.